Search clinical trials for: TCK-276 Placebo

Total 55701 results

Teijin America, Inc.
Parexel

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, France, Hungary, Korea, Republic of, Belgium, Japan, Germany, Canada, Italy, Poland, Czechia, Denmark, Greece, Norway, Romania, Slovakia, United Kingdom
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States
Takeda

Not yet recruiting

A Study of TAK-279 in Healthy Chinese Adults

Healthy Volunteers

China
Takeda
Nimbus Lakshmi, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Poland
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Takeda

Active, not recruiting

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Takeda
Nimbus Lakshmi, Inc.; Innovaderm Research Inc.

Completed

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Canada
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Chemotherapy | Malignant Tumor
Janssen Research & Development, LLC

Completed

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
Takeda

Recruiting

A Study of TAK-279 in Adults With or Without Liver Damage

Healthy Volunteers | Hepatic Impairment

United States
Takeda

Completed

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Type 2 Diabetes Mellitus and Microalbuminuria

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
Design Therapeutics

Completed

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Friedreich Ataxia

United States
Ariston Pharmaceuticals, Inc.

Unknown

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Migraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura

Finland, Netherlands, United Kingdom
Church & Dwight Company, Inc.
KGK Science Inc.

Unknown

A Study to Investigate the Safety and Efficacy of a Probiotic on Gastrointestinal Health in Healthy Adults

Healthy | Gastrointestinal Health

Canada
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

Early Rheumatoid Arthritis

China
Presage Biosciences
Takeda

Completed

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Design Therapeutics, Inc.

Completed

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

Friedreich Ataxia

United States
Aeromics, Inc.
Covance

Completed

Phase 1 Study to Assess AER-271

Stroke | Stroke, Ischemic | Stroke, Acute

United States
Vifor (International) Inc.
Fortrea

Completed

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity)

Sickle Cell Disease

United States, France, Greece, Lebanon, United Kingdom
SIGA Technologies
Biomedical Advanced Research and Development Authority

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat (SIGA246-008)

Smallpox

United States
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
LEO Pharma

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (TRAPEDS 2)

Atopic Dermatitis
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Global Alliance for TB Drug Development

Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
OrsoBio, Inc

Completed

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Healthy Subjects

New Zealand
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom

3

Subscribe